

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTC

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary.)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	09/874,141
--------------------	------------

Filing Date	06/06/2004
-------------	------------

First Named Inventor	DARRELL R ANDERSON
----------------------	--------------------

Art Unit	16.4.4
----------	--------

Examiner Name	Phillip Gambel
---------------	----------------

Attorney Docket Number	037003-0280632
------------------------	----------------

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7 <sup>2</sup>
		BRAMS ET AL., "A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation," International Immunopharmacology, 1 ed., Elsevier Science B.V., p. 277-294, (2001).	
		ROY ET AL., "The Regulation of the Expression of gp39, the CD40 Ligand, on Normal and Cloned CD4+ T Cells," The Journal of Immunology, The American Association of Immunologists, Vol. 151 (No. 5), p. 2497-2510, (September 1, 1993).	
		VAN DEN EERTWEGH ET AL., "In Vivo Expression of CD40 Ligand, Cytokines and Ab Delineate T-B Cells,* J. Exp. Med., The Rockefeller University Press, p. 1555-1565, (November 1993).	

Examiner  
Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation on the front cover. 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.67 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. There will be no direct burden on the public. Any comments or suggestions for improving this form should be sent to the Office of Management and Enterprise Services, Attention: Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. RETURN TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*if you need assistance in completing the form, call 1-800-PTO-9199 and select option 2*